Investment Group adds Genomics Skills-Set to Biohub Partners

Early-stage life sciences venture capital group Coddle Creek Capital (CCC) has announced a multi-million dollar acquisition investment in Eremid Genomic Services LLC, a company focused on provision of genomics data in the areas of human health, agriculture, plant based nutrition and longevity. Originally spun out as the commercial arm of the David H. Murdock Research Institute, the new management structure will drive the company forward as a high-end, scientifically driven genomics partner with enhanced ability to deliver high-quality data using the latest in genomics instruments and automation.

The company will be a key partner and resource for the rapidly growing biotech hub being built on the Institute’s North Carolina Research Campus and for the local and wider genomics community.  With goals to provide access to and guidance on the use of rapidly-evolving Next Generation Sequencing technologies, the company’s experience in delivering complex genomics projects and bioinformatic analyses places it as the perfect CRO partner to meet this, said CCC.

In addition to Eremid, CCC has been a key investor, advisor and/or founder of several co-located companies that will form part of the expanding biotech hub, including:

BrightPath Labs: An advanced AI-driven drug manufacturer

Salubrent Pharma Services: An CDMO focused on advancing the aseptic sterile fill & finish formulation and manufacturing sector.

SNP Therapeutics: A Precision Nutrition company, spun out from the University of North Carolina Chapel Hill Nutritional Research Institute in Kannapolis, NC.

Julian Abery, Chief Business Officer at Eremid commented: “This is an exciting time of growth and development for us. With the support of Coddle Creek Capital, Eremid promises to become a best-in-class genomics CRO. We will deliver scientific excellence to our customers by leveraging decades of research experience and the latest technologies, while making no compromises in our processes. We will focus on areas that influence human health and longevity, including agbiotech, nutrition, and immunooncology research.”

John Allen, General Partner at Coddle Creek Capital, added: “I’m delighted for us to add Eremid Genomic Services to our portfolio. Eremid already provides high-end NGS services to the market, meeting a demand for absolute expertise, reliability and data quality. With our investment, the company will be able to leverage its expertise and instrumentation to provide a truly exceptional service to the wider genomics community and help catalyse further developments in the local area.”

More information online